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Summary
Ehlers-Danlos syndrome (EDS) type VIIC is a recessively
inherited connective-tissue disorder, characterized by ex-
treme skin fragility, characteristic facies, joint laxity,
droopy skin, umbilical hernia, and blue sclera. Like the
animal model dermatosparaxis, EDS type VIIC results
from the absence of activity of procollagen I N-protein-
ase (pNPI), the enzyme that excises the N-propeptide of
type I and type II procollagens. The pNPI enzyme is a
metalloproteinase containing properdin repeats and a
cysteine-rich domain with similarities to the disintegrin
domain of reprolysins. We used bovine cDNA to isolate
human pNPI. The human enzyme exists in two forms:
a long version similar to the bovine enzyme and a short
version that contains the Zn-binding catalytic site but
lacks the entire C-terminal domain in which the pro-
perdin repeats are located. We have identified the mu-
tations that cause EDS type VIIC in the six known af-
fected human individuals and also in one strain of
dermatosparactic calf. Five of the individuals with EDS
type VIIC were homozygous for a CrT transition that
results in a premature termination codon, Q225X. Four
of these five patients were homozygous at three down-
stream polymorphic sites. The sixth patient was ho-
mozygous for a different transition that results in a pre-
mature termination codon, W795X. In the der-
matosparactic calf, the mutation is a 17-bp deletion that
changes the reading frame of the message. These data
provide direct evidence that EDS type VIIC and der-
matosparaxis result from mutations in the pNPI gene.
Received February 12, 1999; accepted for publication May 21,
1999; electronically published June 23, 1999.
Address for correspondence and reprints: Alain Colige, Laboratory
of Connective Tissues Biology, University of Lie`ge, CHU Sart Tilman,
4000 Lie`ge, Belgium; E-mail: LCTB@ulg.ac.be
 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/99/6502-0006$02.00
Introduction
Ehlers-Danlos syndrome (EDS) is a heterogeneous group
of inherited connective-tissue disorders characterized by
altered mechanical properties of skin, joints, blood ves-
sels, and ligaments. At least 10 types and subtypes of
this syndrome have been defined, on the basis of clinical,
genetic, and biochemical criteria (Steinmann et al. 1993).
A simplified classification of EDS into six major types
has been proposed recently (Beighton et al. 1998). Mu-
tations in the genes encoding a1(I), a2(I), a1(III), a1(V),
and a2(V) chains of procollagens, lysyl hydroxylase, and
tenascin-X have been found in different forms of EDS
(Levinson et al. 1993; Steinmann et al. 1993; Toriello
et al. 1996; Wenstrup et al. 1996; Burch et al. 1997; De
Paepe et al. 1997).
EDS type VIIC (MIM 225410) (Nusgens et al. 1992;
Smith et al. 1992; Reardon et al. 1995; Fujimoto et al.
1997) and the related animal disease, dermatosparaxis
(Hanset and Ansay 1967), are recessively inherited con-
nective-tissue disorders. They result from a defect in the
processing of type I procollagen to collagen, with ac-
cumulation in most tissues of molecules that retain the
amino-terminal propeptide (Lenaers et al. 1971). These
precursor molecules self-assemble into abnormal rib-
bonlike fibrils that fail to provide normal tensile strength
to tissues (Pie´rard and Lapie`re 1976; Nusgens et al.
1992; Smith et al. 1992). The defect in the processing
of type I reflects the absence of activity of procollagen
I N-proteinase (pNPI), the enzyme that normally re-
moves the aminopropeptide of type I and type II pro-
collagen (Lapie`re et al. 1971; Colige et al. 1995). The
bovine pNPI enzyme is a member of the metzincin su-
perfamily of metalloproteinases (Colige et al. 1997). In
addition to the zinc-binding catalytic site, pNPI contains
four domains homologous to properdin repeats and a
cysteine-rich region with some similarity to the disin-
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Table 1
PCR Primer Pairs Used for Amplification of Overlapping RT-PCR Fragments from Human and Bovine pNPI Transcripts and






1 330 CGCTTGGTGTCCCACGTGGTGT CCAGCCCATCGCAGTTGCTGAG
2 1,034 TTTGGCCGAGACCTGCACCTGC AGGTAGCGGCTCAGCTCCTGCT
3 1,110 GCATGCAAGGCTATGCTCCTGTCA GGATCTCAAACATCTTGATGTAACCA
4 1,226 CCGGGGAGGTGGTGTCCATGAA CCTACAGAATATTGACTTGTCGCCTTa
5 1,124 ACAACACCACCCGCTCCGTGCA CTGCTTAGCAACTTGGGGCCTATTb
6c 339 CCTGACAACCCCTACTTTTGCAAG GACTGGAAGCAGCGACGCGATCTT
7 191 CTACAAGGACGCCTTCAGCCTCT GGATCTCAAACATCTTGATGTAACCA
8c 217 TTGGGAGGCCAAGGTAGGTGGAT GACTGGAAGCAGCGACGCGATCTT
PCR products:
A 197 GGATGCCAGTTCCAAAACCTTCATT GGCCACGCAGAGTGTCACCTGAAd
B 1,900 CAAGGCCGTGTGCATGTGGTGTAT CGGCTGAGGCTGTCCAGGCTGT
C 101e CACCCGCGTGGAGCCCCTGCT CCAGCCCATCGCAGTTGCTGAG
a CCTACAGAACACTGACTTGTCACCTT for the amplification of bovine mRNA.
b CTGCTCAGAAACTTGGGGCAAAGG for the amplification of bovine mRNA.
c Primer pair allowing the amplification of exon B for spNPI only (see figs. 1 and 3).
d Primer specific for intron sequence situated upstream of the mutation. Other primers were designed from the cDNA sequence.
e In dermatosparactic calves, the amplicon length is 84 bp.
tegrin domain of ADAMs (a disintegrin and metallo-
proteinase).
In this study, we report the cDNA and the amino acid
sequences of human pNPI, compare the human and the
bovine enzymes, and describe the mutations that cause
EDS type VIIC in six unrelated patients and that cause
dermatosparaxis in the Belgian strain of cattle in which
the disease was first identified (Hanset and Ansay 1967).
Patients, Material, and Methods
Patients and Biological Material
Total RNA (Chirgwin et al. 1979) and genomic DNA
(QIAamp Blood kit; Qiagen) were purified from fresh
tissues or from cultured skin fibroblasts derived from
human and bovine nonaffected controls, from five pre-
viously described patients with EDS type VIIC (Nusgens
et al. 1992; Smith et al. 1992; Wertelecki et al. 1992;
Petty et al. 1993; Reardon et al. 1995; Fujimoto et al.
1997), from one additional patient, and from a der-
matosparactic calf (Hanset and Ansay 1967). All cell
strains were used at low passage level, had the charac-
teristic fibroblastic appearance, and had a normal rate
of proliferation in culture.
Clinical Summary of the New Patient
The sixth known infant with EDS type VIIC was a
male infant delivered at 31 wk gestation, because of fetal
distress. Both parents were of Ashkenazi Jewish back-
ground but could not identify common ancestors. He
remained in the intensive-care unit for 2 mo, because of
multiple problems. He was noted to be dysmorphic and
had a large umbilical hernia. The diagnosis of EDS type
VIIC was made when examination of skin by electron
microscopy demonstrated characteristic changes in the
collagen fibrils. The diagnosis was confirmed by dem-
onstration that cultured dermal fibroblasts did not con-
vert type I procollagen to collagen. At the age 8 mo he
was below the 5th percentile in height and weight, had
a gastrostomy tube placed for caloric supplementation,
and was delayed in motor development. His physical
appearance was similar to that of other infants with EDS
type VIIC, in that he had multiple redundant skin folds
at the wrists, elbows, axillae, knees, and groin; was
mildly hirsute; and had grey sclerae, a small chin, and
a slightly widened scar from the removal of the large
umbilical hernia.
Isolation of cDNAs for Human N-Proteinase
Total RNA was isolated from human skin fibroblasts
(CRL1262; American Type Culture Collection) and was
reverse transcribed with oligo-dT and random primers
to cDNA (cDNA synthesis kit; Pharmacia). The cDNA
was then inserted into lambda phage vector (ZapII; Stra-
tagene) to make the cDNA library. The cDNA library
was screened with a [32P]-labeled bovine N-proteinase
cDNA probe (Colige et al. 1997). Nine cDNA inserts of
2–5 kb were isolated and sequenced with an automated
310 Am. J. Hum. Genet. 65:308–317, 1999
instrument (model 377; ABI). Overlapping sequences
were used to define the structures of the full-length
cDNA.
Northern Blot Analysis
Seven micrograms of mRNA were purified from nor-
mal human fibroblasts in culture (PolyATtract mRNA
Isolation System III; Promega), were separated by elec-
trophoresis in 0.9% agarose/formaldehyde gel, and were
transferred to a nylon membrane (Hybond N; Amer-
sham). The filter was prehybridized at 52C for 16 h in
5 # SSPE ( ; 1 mM EDTA;1# SSPE  150 mM NaCl
10 mM NaH2PO4, pH 7.4), 40% deionized formamide,
5 # Denhardt’s solution, 0.1% SDS, 5% dextran sul-
fate, and 100 mg denatured salmon sperm DNA/ml; was
probed for 18 h under the same conditions, with a re-
verse transcription–PCR (RT-PCR) product (fragment 2;
table 1); and was labeled with a[32P]-dATP and a ran-
dom priming labeling kit (Boehringer Mannheim). The
blot was washed at 65C in 0.3 # SSC (1# SSPE 
; 15 mM Na citrate, pH 7.0) and 0.1%150 mM NaCl
SDS before exposure to x-ray film.
PCR and DNA Sequencing
Overlapping RT-PCR products were obtained by use
of the Titan One Tube RT-PCR kit (Boehringer Mann-
heim) and six different pairs of primers (RT-PCR prod-
ucts 1–6; table 1). Both strands of purified products were
sequenced by use of a Thermo-Sequenase radiolabeled
terminator cycle sequencing kit (Amersham, Life Sci-
ence) and human or bovine pNPI sequence–specific
primers (Eurogentec). PCR products were synthesized
from genomic DNA by use of DynazymeTaqDNApoly-
merase (Biometra) and three different pairs of primers,
to amplify portions of DNA that contained either the
W795X mutation or the Q225X mutation (PCR prod-
ucts A and B, respectively [table 1]) or the deletion found
in dermatosparactic calves (PCR product C).
Mutation Identification
To determine if codon Q225 was altered in patient 6,
cDNA was amplified with the sense primer of primer
pair B (table 1) and an antisense primer 174 bp down-
stream (5′-TGCAGCATGCCTGCGTGCCCT-3′) in a
PCR program consisting of 94.5C for 60 s, 52C for
60 s, and 72C for 30 s. The PCR product was purified
on a 1% low-melting-temperature agarose gel (NuSieve
GTG agarose; FMC), and was subsequently extracted
from the gel by use of QIAquickTM spin columns (QIA-
GEN). The antisense amplification primer was used in
an ABI PRISMBigDyeTM Terminator cycle sequencing
reaction, and the products were analyzed by use of the
ABI PRISMTM 310 Genetic Analyzer.
Sequence Determination at Three Polymorphic Sites in
the pNPI Coding Region
To identify the nucleotide at the third position of the
codons H286, D676, and D844, cDNA from fibroblasts
of patient 6 was amplified by use of the following primer
pairs: H286, the sense primer of primer pair B and the
antisense primer of primer pair 2 (table 1); D676, primer
pair 3 (table 1); and D844, the sense primer of pair 4
(table 1) and the antisense primer that was used for
preliminary RT-PCR amplification to assay for the
W795X mutation (35 cycles of 94C for 1.5 min, 54C
for 1 min, and 72C for 1.5 min).
Assembly of the Synthetic Competitor RNA
The sense and antisense strands of a synthetic DNA
template were constructed by ligation of overlapping
phosphorylated oligonucleotides, including oligonucleo-
tide primers used for RT-PCR amplification of pNPI and
spNPI mRNA (see RT-PCR Assay, below). Full length
products were then purified and cloned into pSPT18
transcription vector (SP6/T7 transcription kit; Boehrin-
ger Mannheim). Synthetic RNA was generated from the
linearized template plasmid by use of SP6 RNA poly-
merase and was purified (High Pure RNA Isolation kit;
Boehringer Mannheim) and quantitated. RT-PCR am-
plification of this synthetic RNA was performed with
pNPI or spNPI primer-generated products of 265 bp and
262 bp that were larger than those obtained from the
wild-type mRNA (191 bp and 217 bp, respectively).
RT-PCR Assay
The RT-PCR amplifications were performed in an au-
tomated instrument (GeneAmp PCR system 2400 using
a GeneAmp Thermostable rTth Reverse Transcriptase
RNA PCR kit; Perkin-Elmer) with two different pairs of
a[32P]-labeled primers (T4 polynucleotide kinase; Boeh-
ringer Mannheim). The primer pairs specifically ampli-
fied either the 3′ end of human and bovine pNPI and
lpNPI mRNA (table 1; RT-PCR product 7; bp
2043–2233 of the coding sequence) or the human spNPI
mRNA (table 1; RT-PCR product 8; bp 43–259 of exon
B) (fig. 4). For quantitative RT-PCR measurements, 10
ng of total RNA and a known copy number of standard
synthetic RNA were used per 25 ml reaction mixture
(final volume). The RT step (70C for 15 min) was fol-
lowed by a 2-min incubation at 95C, for denaturation
of RNA-DNA heteroduplexes, and then by amplification
for 30 cycles. The PCR conditions were 94C for 15 s,
66C for 20 s and 72C for 10 s. Samples were analyzed
by autoradiography after electrophoresis on a 10%poly-
acrylamide gel. The films were assayed by densitometry
(Imaging Densitometer model GS-700; Bio-Rad, Life
Science).
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Figure 1 Northern blot analysis of human pNPI gene transcripts. Seven micrograms of mRNA extracted from human fibroblasts in culture
were separated onto formaldehyde/agarose gel, transferred on nylon membrane, and hybridized with a labeled cDNA probe obtained by PCR.
The double arrow indicates the region of the mRNAs recognized by the probe. Electrophoretic mobility of RNA molecular-weight markers (in
bases) is indicated on the left. After autoradiography, three main bands are visible (lpNPI, pNPI, and spNPI). The structure of these three
transcripts is represented on the right. Boxes A–C are exons reported in figure 3, and unblackened boxes represent multiexonic cassettes (not
to scale). AATAAA polyadenylation signals (*) and starts and stops of translation are also indicated.
Allele-Specific RT-PCR Assay for the W795X Mutation
A preliminary RT-PCR amplification (Titan One Tube
RT-PCR kit; Boehringer Mannheim) was performed
with oligonucleotide primers (sense, 5′-CCGGGGA-
GGTGGTGTCCATGAA-3′, from bp 1991–2012 of the
coding sequence; anti-sense, 5′-CGGCGGCAGCCA-
TACTTGGTGAA-3′ from bp 2648–2626) which do not
discriminate between the two alleles. RT-PCR products
were then purified on agarose gels and were diluted in
order to achieve the same cDNA concentration in each
sample. For allele-specific PCR amplification, the anti-
sense oligonucleotide (5′-GGGATGACCAGAACGGT-
GATGGT-3′;81 to59 if the ArGmutation is defined
as 1) was 32P-labeled to allow the quantitation of PCR
products. The allele specificity was obtained by use of
sense primers that had either a G (for the normal allele,
5′- GCCATGGGCGTGGATTG-3′) or an A (for the mu-
tated allele; 5′-TGCCATGGGCGTGGATTA-3′) at the 3′
end. To improve specificity, a similar mismatch was in-
troduced in both primers, changing G at position 3 to
T (underlined in the sequences). Although this change
moderately decreased PCR amplification of the specific
allele, amplification of the other allele was completely
prevented. Seventeen cycles of amplification (94C for
15 s; 58C for 15 s; and 72C for 10 s) were performed
with 1 ng preamplified cDNA, 4 pmol each oligonu-
cleotide, and 0.4 U Taq DNA polymerase (Dynazyme;
Biometra), for each 20 ml sample. PCR products were
analyzed by electrophoresis through a 10% polyacryl-
amide gel and by autoradiography.
Results
Isolation of Multiple Human cDNAs
We used bovine pNPI cDNA clones (Colige et al.
1997) to screen a human cDNA library. Overlapping
clones revealed two types of cDNA that differed both
by size (lpNPI, 6,796 bp; and spNPI, 2,137 bp) and by
the sequence of the 3′ ends. To measure their relative
abundance and to search for additional transcripts, a
northern analysis was performed with a probe that hy-
bridized to the 5′ end of both products (fig. 1). In ad-
dition to the two expected mRNAs, a third message, of
∼3,700 nucleotides (pNPI), was detected. Sequencing re-
vealed that this transcript resulted from the use of an
AATAAA signal situated at the beginning of the 3′ non-
coding sequence of lpNPI mRNA (fig. 1). The two longer
transcripts encoded an identical 1,211-amino-acid pro-
tein that displayed 93% identity with the bovine enzyme
(fig. 2). The highest similarity was detected around the
Zn-binding catalytic site, with no substitutions over
a 111-amino-acid sequence and only four substitutions
over a 305-amino-acid sequence. Other specific features
of the bovine enzyme (four properdin repeats, two po-
tential cleavage sites by mammalian subtilisins, one
RGD sequence, and potential glycosylation sites mainly
in the C-terminal domain [Colige et al. 1997]) were con-
served, suggesting that these domains are important for
the biological properties of pNPI.
The shorter transcript (spNPI) was identical to the
long cDNAs, over the first 1,710 nucleotides, but the
large 3′ end of the long forms was replaced by a 313-
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Figure 2 Deduced amino acid sequences of human and bovine pNPI. The human pNPI is the upper line, and the bovine sequence is the
lower line (only positions where amino acids differ from those in the human sequence are shown). The two enzymes contain a signal peptide,
composed mainly of Leu and Ala residues. Two potential cleavage sites, by mammalian subtilisins—RXRR and RRRXRR—and an RGD
sequence are indicated in boldface at, respectively, amino acid residues 85–88, 254–259, and 691–693 of the human sequence. Potential
glycosylation sites are in italic and underlined. The Zn-binding site and Met turn, the properdin repeats, and the positions where mutations
were detected are indicated above the related sequences. The start of divergence, in human, between pNPI and spNPI is also indicated. For
spNPI, the entire sequence downstream of Lys 543 is replaced by an unrelated 23-amino-acid sequence (FRPGAVAHACYPSTLGGQGRWIA
encoded by 5′-TTCAGGCCGGGCGCGGTGGCTCATGCCTGTTATCCCAGCACTTTGGGAGGCCAAGGTAGGTGGATCGCCTGA-3′).
base sequence that terminated with a polyadenylation
signal (AATAAA). Partial sequencing of this region of
the gene indicated that this signal was located within an
intronic sequence of pNPI and lpNPI pre-mRNAs. The
spNPI message resulted from retention of a portion of
this intron and the use of this polyadenylation signal
(fig. 3). The open reading frame of the short message
encoded a protein in which the entire C-terminal domain
(His 544–Phe 1211) found in pNPI was replaced by a
different 23-amino-acid sequence (fig. 2). The spNPI
contains the Zn-binding catalytic site but lacks most
of the potential glycosylation sites and the four proper-
din repeats that are thought to be important for inter-
molecular interactions (Tuszynski et al. 1992; Schultz-
Cherry et al. 1995).
Mutations in pNPI in EDS Type VIIC
Once the human sequences were known, we searched
for the molecular defects responsible for EDS VIIC in
six unrelated individuals (Nusgens et al. 1992; Smith et
al. 1992; Wertelecki et al. 1992; Petty et al. 1993; Rear-
don et al. 1995; Fujimoto et al. 1997; present study).
RT-PCR assays demonstrated that mRNAs for pNPI
were present in fibroblasts of four of the patients (fig.
4). The corresponding cDNAs were sequenced to iden-
tify mutations. In patient 1 (Nusgens et al. 1992), a GrA
transition (2384GrA of the coding sequence) was found
that changed the TGG tryptophan codon at position 795
of pNPI to a TAG stop codon (W795X) (figs. 1 and 5A).
If translated, the resulting pNPI would contain the Zn-
binding catalytic site and the first properdin repeat but
would lack most of the C-terminus. Interestingly, this
mutation does not alter the sequence of spNPI.
Sequence determination of the pNPI cDNA from fi-
broblasts of the parents of patient 1 revealed only the
normal TGG codon (fig. 5A). At the genomic level, both
parents were heterozygous for the wild-type and mutant
alleles, whereas the patient was homozygous for the mu-
tant allele (fig. 5B). To determine if the transcript with
the premature-termination codon was present at low
level in parental fibroblasts, an allele-specific RT-PCR
assay was used (fig. 5C). With an oligonucleotide pair
that allowed the amplification of the mutated allele, a
strong signal was observed for the patient and a faint
one was observed for both parental samples, consistent
with nonsense-mediated decay of the altered message
(Baserga and Benz 1992). Two different pairs of primers
were used to measure the relative amounts of mRNA
for spNPI and pNPI (see Assembly of the Synthetic Com-
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Figure 3 Alternative splicing of pNPI primary transcript. Alter-
native splicing and alternative use of an AATAAA polyadenylation
signal (*) present in the middle of the pNPI gene are represented.
Intronic sequences are represented by thick lines and exons are rep-
resented by boxes (A–C). Alternative splicing events producing spNPI
or the two longer transcripts are indicated, respectively, by dotted or
dashed lines.
Figure 4 Analysis of pNPI and spNPI expression. The mRNA
steady-state levels were assayed by RT-PCR using two different pairs
of a[32P ]-labeled primers and a synthetic RNA as an internal standard
to monitor the efficiency of RT-PCR amplification. PCR-amplified
products were separated on 10% polyacrylamide gels, were visualized
after autoradiography, and were quantified. A, First pair of primers,
which allowed the amplification of a 191-bp DNA product from pNPI
mRNA and of a 265-bp product from the synthetic control RNA. The
region of pNPI mRNA amplified with these primers is indicated by
the double arrow. B, Second pair of primers, which allowed the am-
plification of a 217-bp product from the exon present only in spNPI
mRNA (exon B; fig. 1) and of a 262-bp fragment from the control
synthetic RNA. The transcript structure is as shown in figs. 1 and 3.
In addition to two-fold serial dilutions of total RNA from a normal
individual used as quantification control, total RNA (10 ng) from
various sources was assayed. Lanes 1–10; Skin fibroblasts in culture
from a normal individual (lanes 1–4), father of patient 1 (lane 5),
mother of patient 1 (lane 6), patient 1 (lane 7), patient 2 (lane 8),
patient 3 (lane 9), patient 4 (lane 10). Lane 11, Human foreskin. Lanes
12–13, Placental villi at the first (lane 12) and the third trimester (lane
13). Lanes 14 and 15, skin fibroblasts from a normal (lane 14) or a
dermatosparactic calf (lane 15). Lane 16, bovine skin.
petitor RNA, above) (fig. 4). For spNPI mRNA, which
is not altered by the mutation, similar levels were de-
tected in the cells of the normal individual, patient 1,
and her parents (fig. 4B, lanes 1 and 4–7). In contrast,
the pNPI mRNA steady-state level was reduced in cells
from patient 1 and her parents (fig. 4A, lanes 5-7) com-
pared with both that in the control individual (fig. 4A,
lane 1) and that in spNPI mRNA.
The cDNA synthesized from RNA isolated from the
cultured fibroblasts of patients 2 (Smith et al. 1992;Wer-
telecki et al. 1992), 3 (Petty et al. 1993), 4 (Fujimoto et
al. 1997), and 6 (present study) were sequenced. The
same CrT transition (673CrT of the coding sequence)
was found that changed a Gln codon (CAG) to a stop
codon (TAG) (Q225X) (fig. 6). In contrast to the mu-
tation in patient 1, if this mutation allowed translation
to occur, it would lead to truncation of spNPI and pNPI,
such that both would lack the Zn-binding catalytic
site (fig. 1).
The sequences of the genomic DNA from these four
patients and from another unrelated patient (patient 5),
from whom only genomic DNA was available (Reardon
et al. 1995), indicated that all were homozygous at the
mutation site (not shown). Samples from parents were
available only for patients 2 and 6; analysis of the se-
quence indicated that all four patients were heterozygous
for the mutation. Analysis of cDNA and genomic DNA
from the parental cells of patient 2 was consistent with
low levels of the mutation-bearing mRNA. Nonsense-
mediated decay probably accounted for the reduction of
both pNPI and spNPI messages in cells from patients
2–4, compared with the level measured in the normal
individual (fig. 4).
When the cDNA or the genomic DNA from patients
2–5 was sequenced, all patients were found to be ho-
mozygous for the third-position nucleotides in the co-
dons for histidine at position 286 (CAT) and for the
aspartic residues at positions 676 (GAT) and 844 (GAT).
In contrast, patient 6 was homozygous at position 286
but was heterozygous at the two other positions (GAC/
T).
Mutation in pNPI in Bovine Dermatosparaxis
In the dermatosparactic calf, electrophoresis of short
RT-PCR products demonstrated that there was a dele-
tion in the 5′ end of the message (Fig. 7A). Sequence
determination showed a 3-bp change, followed by a 17-
bp deletion, in the beginning of the coding sequence,
that changed the reading frame of the message (fig. 7B).
If the mRNA is stable, this mutation would result in the
synthesis of a truncated protein in which the entire se-
quence downstream of Val 153, including the catalytic
site, would be replaced by a 24-amino-acid sequence (V-
V-R-G-A-Q-Q-L-R-W-A-G-W-P-D-P-Y-G-R-G-G-I-L-Y-
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Figure 5 Mutation analyses of pNPI in the family of patient 1.
DNA sequences of PCR-amplified cDNA (A) and genomic DNA (B)
derived from a nonaffected control individual, from patient 1, and
from her parents are illustrated. At the cDNA level (A), one mutation
that changed a Trp codon to a stop codon (W795X) was found only
in patient 1. At the genomic level, patient 1 is homozygous, and her
parents are heterozygous (B). Allele-specific PCR amplification was
performed on RNA from the same four individuals (C).
Figure 6 Mutation analysis for pNPI in patients 2–4. Sequences
of the PCR-amplified cDNA derived from a normal individual and
from patients 2–4 are illustrated. The same mutation that changed the
Gln 225 codon to a stop codon Q225X) was observed in all three
patients, as well as in patients 5 and 6 (not illustrated in this figure).
stop) (fig. 2). PCR analysis of the genomic DNA (PCR
product C; table 1) revealed that dermatosparactic calves
are homozygous for the deletion (not shown).
Discussion
The data presented here provide insights into the bi-
ology of the procollagen I N-proteinase and give direct
evidence that EDS type VIIC and bovine dermatospar-
axis result from alterations in the pNPI gene. A previous
study had shown that procollagen I N-proteinase activity
was not detectable in skin from patient 1 (Nusgens et
al. 1992). Since the catalytic site of pNPI in this patient
is not affected by the mutation, this finding means either
that pNPI cannot be translated from the mutatedmRNA
or that the C-terminal region of pNPI contains domain(s)
crucial for enzyme function. Quantitative RT-PCR as-
says (not shown) indicate that spNPI mRNA is present
in the cytoplasm of fibroblasts, suggesting that it is prob-
ably translated. The spNPI transcript is not altered by
the mutation which completely suppresses the procol-
lagen I N-proteinase activity in patient 1, so it is unlikely
that spNPI can efficiently process the N-propeptide. Re-
cently, it was shown that the C-terminal domain of col-
lagenase 3 (MMP13) is required for this enzyme to bind
to triple-helical type I collagen and to perform its cat-
alytic activity (Knau¨per et al. 1997). We think that the
properdin repeats, which are present in pNPI but are
absent in spNPI and in pNPI of patient 1, could have a
similar function—that is, to promote the binding of the
active enzyme to type I procollagen. Thus, if the protein
were translated from the abnormal message synthesized
by the cells from patient 1, it would not be active. Anal-
ysis of cDNA of the other patients with EDS VIIC in-
dicates that a mutation that prevents the synthesis of
both spNPI and pNPI (patients 2–6) does not result in
a phenotype more severe than amutation that suppresses
the synthesis of only pNPI (patient 1). These results fur-
ther support the concept that spNPI has no significant
aminoprocollagen peptidase activity. A physiological
role for spNPI is, nonetheless, suggested by the relatively
high level of its mRNA in skin and cultured fibroblasts
and by variation of the pNPI/spNPI mRNA ratio in vivo
(fig. 4A and B, lanes 11–13). Similar observations have
been made for the procollagen carboxy-peptidase, also
known as “BMP1” (Kessler et al. 1996; Li et al. 1996;
Lee et al. 1997). This enzyme is responsible for the ex-
cision of the C-propeptide of type I, type II, and type
III procollagens and can be detected, at the mRNA level,
in the form of alternatively spliced transcripts that are
differently expressed in various tissues (Takahara et al.
1994).
We were surprised that five unrelated individuals with
EDS type VIIC who lived in the United States (Smith et
al. 1992;Wertelecki et al. 1992; Petty et al. 1993; present
study), in England (Reardon et al. 1995), and in Mexico
(Fujimoto et al. 1997) had the same mutation. The mu-
tation in patients 2–5 could be on the same allelic back-
ground, as judged on the basis of three other variants
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Figure 7 Mutation analysis of pNPI in dermatosparactic calf.
A, Electrophoresis on agarose gel of RT-PCR products derived from
normal (N) or dermatosparactic (D) calf mRNA. B, Sequence of the
PCR-amplified cDNA derived from normal or dermatosparactic calf,
around the deletion detected in panel A.
in the coding sequence of the gene. All have a T as the
third base of the codons for His 286 (CAT), Asp 676
(GAT), and Asp 844 (GAT), whereas C or CT was
detected in seven other individuals. In patient 6, who is
homozygous at position 286 but is heterozygous at the
two other positions (GAC/T), it is not clear whether
there is one additional allele or two since the phase re-
lationships of the sequence variants have not been de-
termined. An extended haplotype for the region sur-
rounding the mutation has not been determined for any
of the patients. The ethnic backgrounds of these five
affected individuals differ: three are Ashkenazi Jewish ,
one is Hispanic/Mexican, and one is from an American
family of undetermined background. The mutation ap-
pears to be on a different background in one of the
Ashkenazi alleles. Thus the mutation appears to have
occurred at least twice but is probably uncommon, since
only five affected children have been identified. The mu-
tation is not within a type of sequence in which recurrent
mutation is frequent.
In cattle, fibroblasts from only one dermatosparactic
calf were examined. However, there is little doubt that
other affected calves have the same genomic alteration,
since all known dermatosparactic calves in Belgium orig-
inated from the Belgian Blue cattle breed, which was
selected by intensive inbreeding (Grobet et al. 1997) and
had, as a common ancestor, the same bull. In derma-
tosparactic calves, the deletion in pNPI gene is situated
30 bp upstream of an intron/exon boundary as deter-
mined on the basis of human genomic DNA analysis. If
it is assumed that the gene structure is the same in cattle,
this would suggest that the alteration observed in der-
matosparaxis is a true deletion, not a deletion resulting
from a splice-site mutation and the use of a new donor
site.
In EDS type VIIC and dermatosparaxis, the skin is
more severely affected than other collagen-rich tissues
(tendons, blood vessels, and bones) and this variation is
correlated with the level of morphological alteration of
the type I collagen fibrils. In cattle, the N-terminus of
procollagen is barely processed in skin but is more ex-
tensively cleaved in bone and tendon. Since the mutation
reported here would prevent the synthesis of active
pNPI, this suggests that another enzyme, which has tis-
sue-specific expression, can remove the amino-terminus
of type I procollagen, although at a lower rate than that
at which pNPI is removed. Recently, two proteins that
have a high sequence homology with pNPI and that
contain similar domains, including properdin repeats,
have been described. One is a mouse protein associated
with inflammation (Kuno et al. 1997), and the other was
detected in human brain and placenta (Nagase et al.
1997). Their physiological roles have not been deter-
mined yet. However, the regulation of their expression
and their tissue specificity suggest various functions for
members of this new subfamily of metalloproteinases.
These two metalloproteinases, or others of the same sub-
family that have yet to be identified, are candidates for
an alternative processing pathway of type I procollagen.
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